Share Price and Basic Stock Data
Last Updated: November 20, 2025, 10:32 pm
| PEG Ratio | 14.63 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Genomic Valley Biotech Ltd operates in the Seeds/Tissue Culture/Bio Technology industry, with a current market capitalization of ₹9.28 Cr and a share price of ₹30.4. The company has reported fluctuating revenue trends over the past few quarters. For instance, sales peaked at ₹2.72 Cr in March 2023 but fell to ₹0.17 Cr by March 2024, reflecting significant volatility. Quarterly sales figures also demonstrate inconsistency, with revenues of ₹1.03 Cr in June 2022 dropping sharply to as low as ₹0.02 Cr in September 2022, followed by a modest recovery to ₹0.21 Cr by September 2024. This erratic performance raises concerns about the company’s market positioning and operational capabilities in a highly competitive sector. The trailing twelve months (TTM) revenue stood at ₹0.66 Cr, indicating a need for strategic initiatives to stabilize and enhance revenue generation.
Profitability and Efficiency Metrics
In terms of profitability, Genomic Valley Biotech reported a net profit of ₹0.10 Cr, yielding a price-to-earnings (P/E) ratio of 92.8, which is significantly higher than typical sector averages, suggesting that the stock may be overvalued relative to its earnings. The operating profit margin (OPM) stood at 33.33%, indicating a solid ability to manage costs relative to sales. However, the company also recorded periods of negative operating profit, particularly in the earlier quarters of FY 2022. The return on equity (ROE) was reported at 9.68%, while the return on capital employed (ROCE) was 11.8%, reflecting moderate efficiency in utilizing shareholder equity and capital for generating profits. The cash conversion cycle is alarmingly high at 1,429.58 days, indicating inefficiencies in converting sales into cash, which could strain liquidity if not addressed.
Balance Sheet Strength and Financial Ratios
Genomic Valley Biotech’s balance sheet reveals no reported borrowings, which suggests a conservative approach to financing. However, the absence of reserves raises concerns about the company’s ability to fund growth or weather financial downturns. The current ratio is reported at 5.73, indicating robust liquidity and an ability to cover short-term liabilities. The company’s price-to-book value (P/BV) ratio stood at 4.59x, which is elevated compared to typical industry standards, hinting at potential overvaluation. The interest coverage ratio (ICR) is at 0.00x, indicating that the company has no interest-bearing debt, which is a positive aspect but also raises questions about potential growth financing. These financial ratios indicate a mixed picture of financial health, with strong liquidity but potentially unsustainable valuations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Genomic Valley Biotech shows a significant stake held by promoters, who own 46.72% as of June 2025, down from 67.85% in December 2022. This decline in promoter holding could raise concerns about their confidence in the company’s future. Conversely, public ownership has increased to 53.29%, reflecting growing interest from retail investors. The number of shareholders has also seen substantial growth, rising from 377 in December 2022 to 2,459 by June 2025, indicating an expanding investor base. This shift may suggest a changing narrative, but the declining promoter stake could be interpreted as a lack of confidence in the company’s prospects. Overall, while there is heightened public interest, the decreasing promoter ownership could potentially dampen investor sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Genomic Valley Biotech faces several challenges and opportunities. The company’s significant cash conversion cycle poses a risk to liquidity and operational efficiency, necessitating immediate management strategies to improve working capital. Additionally, the high P/E ratio suggests that the stock may be overvalued unless earnings improve significantly. On the positive side, the absence of debt provides a solid foundation for potential growth through equity financing. The increasing public shareholding indicates a burgeoning interest, which could lead to more favorable market conditions if the company successfully stabilizes its revenues. If Genomic Valley can address its operational inefficiencies and leverage its liquidity for growth, it may enhance profitability and investor confidence, thereby positioning itself more favorably in the biotechnology sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Genomic Valley Biotech Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Ltd | 9.28 Cr. | 30.4 | 108/27.2 | 92.8 | 12.8 | 0.00 % | 11.8 % | 9.68 % | 10.0 |
| Genesis IBRC India Ltd | 210 Cr. | 162 | 185/16.6 | 6.42 | 0.00 % | 51.6 % | 51.6 % | 10.0 | |
| Shreeoswal Seeds & Chemicals Ltd | 122 Cr. | 13.4 | 22.8/10.7 | 12.2 | 5.23 | 0.00 % | 9.88 % | 8.41 % | 2.00 |
| Nath Bio-Genes (India) Ltd | 309 Cr. | 161 | 239/138 | 6.55 | 362 | 1.24 % | 7.35 % | 6.77 % | 10.0 |
| Continental Seeds and Chemicals Ltd | 21.2 Cr. | 19.3 | 43.0/19.3 | 27.6 | 27.0 | 0.00 % | 4.24 % | 2.87 % | 10.0 |
| Industry Average | 213.67 Cr | 77.22 | 34.79 | 82.69 | 0.25% | 16.97% | 15.87% | 8.40 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.03 | 0.02 | 0.67 | 1.00 | 0.06 | 0.07 | 0.04 | 0.00 | 0.16 | 0.21 | 0.22 | 0.26 | 0.09 |
| Expenses | 1.08 | 0.05 | 0.63 | 0.07 | 0.03 | 0.05 | 0.02 | 0.04 | 0.03 | 0.07 | 0.06 | 0.26 | 0.06 |
| Operating Profit | -0.05 | -0.03 | 0.04 | 0.93 | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.14 | 0.16 | 0.00 | 0.03 |
| OPM % | -4.85% | -150.00% | 5.97% | 93.00% | 50.00% | 28.57% | 50.00% | 81.25% | 66.67% | 72.73% | 0.00% | 33.33% | |
| Other Income | 0.52 | 0.10 | -0.89 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.46 | 0.06 | -0.85 | 0.98 | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.15 | 0.16 | 0.00 | 0.03 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Net Profit | 0.46 | 0.06 | -0.85 | 0.98 | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.15 | 0.16 | -0.08 | 0.02 |
| EPS in Rs | 1.51 | 0.20 | -2.78 | 3.21 | 0.10 | 0.07 | 0.07 | -0.13 | 0.43 | 0.49 | 0.52 | -0.26 | 0.07 |
Last Updated: August 19, 2025, 2:45 pm
Below is a detailed analysis of the quarterly data for Genomic Valley Biotech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.09 Cr.. The value appears to be declining and may need further review. It has decreased from 0.26 Cr. (Mar 2025) to 0.09 Cr., marking a decrease of 0.17 Cr..
- For Expenses, as of Jun 2025, the value is 0.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.26 Cr. (Mar 2025) to 0.06 Cr., marking a decrease of 0.20 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.03 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.03 Cr..
- For OPM %, as of Jun 2025, the value is 33.33%. The value appears strong and on an upward trend. It has increased from 0.00% (Mar 2025) to 33.33%, marking an increase of 33.33%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.03 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.03 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.02 Cr.. The value appears strong and on an upward trend. It has increased from -0.08 Cr. (Mar 2025) to 0.02 Cr., marking an increase of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.07. The value appears strong and on an upward trend. It has increased from -0.26 (Mar 2025) to 0.07, marking an increase of 0.33.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:16 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.09 | 0.03 | 0.11 | 0.44 | 0.59 | 0.99 | 0.85 | 0.21 | 0.07 | 2.72 | 0.17 | 0.84 | 0.66 |
| Expenses | 0.08 | 0.07 | 0.54 | 0.48 | 0.49 | 0.57 | 0.30 | 0.34 | 0.45 | 1.84 | 0.15 | 0.40 | 0.47 |
| Operating Profit | 0.01 | -0.04 | -0.43 | -0.04 | 0.10 | 0.42 | 0.55 | -0.13 | -0.38 | 0.88 | 0.02 | 0.44 | 0.19 |
| OPM % | 11.11% | -133.33% | -390.91% | -9.09% | 16.95% | 42.42% | 64.71% | -61.90% | -542.86% | 32.35% | 11.76% | 52.38% | 28.79% |
| Other Income | 0.01 | 0.07 | 0.16 | 0.01 | 0.03 | 0.01 | 0.01 | 0.00 | 0.50 | -0.22 | 0.00 | 0.00 | 0.00 |
| Interest | 0.01 | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.18 | 0.18 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.01 | 0.05 | 0.04 | 0.08 | 0.19 | 0.18 | 0.19 | 0.08 | 0.01 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.01 | -0.01 | -0.34 | -0.07 | 0.05 | 0.24 | 0.20 | -0.50 | 0.00 | 0.65 | 0.02 | 0.44 | 0.19 |
| Tax % | 0.00% | 0.00% | -2.94% | 0.00% | 40.00% | 0.00% | -40.00% | 12.00% | 0.00% | 0.00% | 20.45% | ||
| Net Profit | 0.00 | -0.01 | -0.33 | -0.07 | 0.03 | 0.23 | 0.29 | -0.56 | -0.01 | 0.65 | 0.02 | 0.36 | 0.10 |
| EPS in Rs | 0.00 | -0.03 | -1.08 | -0.23 | 0.10 | 0.75 | 0.95 | -1.83 | -0.03 | 2.13 | 0.07 | 1.18 | 0.33 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -3200.00% | 78.79% | 142.86% | 666.67% | 26.09% | -293.10% | 98.21% | 6600.00% | -96.92% | 1700.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 3278.79% | 64.07% | 523.81% | -640.58% | -319.19% | 391.32% | 6501.79% | -6696.92% | 1796.92% |
Genomic Valley Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 40% |
| 5 Years: | 0% |
| 3 Years: | 129% |
| TTM: | 189% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 44% |
| 5 Years: | 4% |
| 3 Years: | 42% |
| TTM: | 92% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | % |
| 1 Year: | -42% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 2% |
| 3 Years: | 12% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 3:36 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 960.30 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 486.67 | ||||||
| Days Payable | 17.38 | |||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 1,429.58 |
| Working Capital Days | 7,746.11 | -8,881.67 | -1,659.09 | -514.32 | -804.24 | 55.30 | -176.06 | -1,251.43 | 4,849.29 | 221.42 | 4,530.29 | 916.85 |
| ROCE % | 0.41% | 0.35% | -5.84% | -0.57% | 0.57% | 4.17% | 5.96% | -5.10% | -8.54% | 28.48% | 0.57% | 11.83% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.17 | 0.05 | 2.12 | -0.03 | -1.83 |
| Diluted EPS (Rs.) | 1.17 | 0.05 | 2.12 | -0.03 | -1.83 |
| Cash EPS (Rs.) | 1.17 | 0.05 | 2.15 | 0.24 | -1.21 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 12.76 | 11.60 | 11.55 | 9.42 | 14.69 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 12.76 | 11.60 | 11.55 | 9.42 | 14.69 |
| Revenue From Operations / Share (Rs.) | 2.76 | 0.54 | 8.91 | 0.23 | 0.68 |
| PBDIT / Share (Rs.) | 1.45 | 0.05 | 3.02 | -0.96 | -0.44 |
| PBIT / Share (Rs.) | 1.45 | 0.04 | 2.99 | -1.24 | -1.06 |
| PBT / Share (Rs.) | 1.45 | 0.04 | 2.12 | -1.38 | -1.64 |
| Net Profit / Share (Rs.) | 1.17 | 0.04 | 2.12 | -0.03 | -1.83 |
| PBDIT Margin (%) | 52.60 | 9.83 | 33.83 | -416.43 | -64.94 |
| PBIT Margin (%) | 52.30 | 9.17 | 33.54 | -535.97 | -155.88 |
| PBT Margin (%) | 52.30 | 9.17 | 23.83 | -596.37 | -241.16 |
| Net Profit Margin (%) | 42.19 | 9.19 | 23.81 | -13.23 | -268.67 |
| Return on Networth / Equity (%) | 9.13 | 0.42 | 18.38 | -0.32 | -12.45 |
| Return on Capital Employeed (%) | 11.32 | 0.42 | 25.89 | -10.55 | -4.80 |
| Return On Assets (%) | 8.17 | 0.35 | 14.66 | -0.24 | -7.33 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 |
| Total Debt / Equity (X) | 0.00 | 0.16 | 0.17 | 0.00 | 0.34 |
| Asset Turnover Ratio (%) | 0.19 | 0.03 | 0.66 | 0.01 | 0.02 |
| Current Ratio (X) | 5.73 | 3.68 | 2.88 | 5.31 | 0.18 |
| Quick Ratio (X) | 5.10 | 3.68 | 2.88 | 5.31 | 0.18 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| Interest Coverage Ratio (X) | 0.00 | 0.00 | 0.00 | -6.89 | -0.76 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | 0.00 | -9.05 | -2.15 |
| Enterprise Value (Cr.) | 17.85 | 11.20 | 7.21 | 7.56 | 8.74 |
| EV / Net Operating Revenue (X) | 21.15 | 67.84 | 2.65 | 107.10 | 42.02 |
| EV / EBITDA (X) | 40.21 | 689.51 | 7.83 | -25.72 | -64.70 |
| MarketCap / Net Operating Revenue (X) | 21.21 | 64.23 | 2.44 | 107.14 | 34.64 |
| Price / BV (X) | 4.59 | 2.99 | 1.88 | 2.63 | 1.61 |
| Price / Net Operating Revenue (X) | 21.21 | 64.28 | 2.44 | 107.14 | 34.65 |
| EarningsYield | 0.01 | 0.00 | 0.09 | 0.00 | -0.07 |
After reviewing the key financial ratios for Genomic Valley Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 5. It has increased from 0.05 (Mar 24) to 1.17, marking an increase of 1.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 5. It has increased from 0.05 (Mar 24) to 1.17, marking an increase of 1.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 3. It has increased from 0.05 (Mar 24) to 1.17, marking an increase of 1.12.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 12.76. It has increased from 11.60 (Mar 24) to 12.76, marking an increase of 1.16.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 12.76. It has increased from 11.60 (Mar 24) to 12.76, marking an increase of 1.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 2.76. It has increased from 0.54 (Mar 24) to 2.76, marking an increase of 2.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 2. It has increased from 0.05 (Mar 24) to 1.45, marking an increase of 1.40.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 0.04 (Mar 24) to 1.45, marking an increase of 1.41.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 0.04 (Mar 24) to 1.45, marking an increase of 1.41.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 2. It has increased from 0.04 (Mar 24) to 1.17, marking an increase of 1.13.
- For PBDIT Margin (%), as of Mar 25, the value is 52.60. This value is within the healthy range. It has increased from 9.83 (Mar 24) to 52.60, marking an increase of 42.77.
- For PBIT Margin (%), as of Mar 25, the value is 52.30. This value exceeds the healthy maximum of 20. It has increased from 9.17 (Mar 24) to 52.30, marking an increase of 43.13.
- For PBT Margin (%), as of Mar 25, the value is 52.30. This value is within the healthy range. It has increased from 9.17 (Mar 24) to 52.30, marking an increase of 43.13.
- For Net Profit Margin (%), as of Mar 25, the value is 42.19. This value exceeds the healthy maximum of 10. It has increased from 9.19 (Mar 24) to 42.19, marking an increase of 33.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.13. This value is below the healthy minimum of 15. It has increased from 0.42 (Mar 24) to 9.13, marking an increase of 8.71.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.32. This value is within the healthy range. It has increased from 0.42 (Mar 24) to 11.32, marking an increase of 10.90.
- For Return On Assets (%), as of Mar 25, the value is 8.17. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 8.17, marking an increase of 7.82.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.19. It has increased from 0.03 (Mar 24) to 0.19, marking an increase of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 5.73. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 5.73, marking an increase of 2.05.
- For Quick Ratio (X), as of Mar 25, the value is 5.10. This value exceeds the healthy maximum of 2. It has increased from 3.68 (Mar 24) to 5.10, marking an increase of 1.42.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 17.85. It has increased from 11.20 (Mar 24) to 17.85, marking an increase of 6.65.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 21.15. This value exceeds the healthy maximum of 3. It has decreased from 67.84 (Mar 24) to 21.15, marking a decrease of 46.69.
- For EV / EBITDA (X), as of Mar 25, the value is 40.21. This value exceeds the healthy maximum of 15. It has decreased from 689.51 (Mar 24) to 40.21, marking a decrease of 649.30.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 21.21. This value exceeds the healthy maximum of 3. It has decreased from 64.23 (Mar 24) to 21.21, marking a decrease of 43.02.
- For Price / BV (X), as of Mar 25, the value is 4.59. This value exceeds the healthy maximum of 3. It has increased from 2.99 (Mar 24) to 4.59, marking an increase of 1.60.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 21.21. This value exceeds the healthy maximum of 3. It has decreased from 64.28 (Mar 24) to 21.21, marking a decrease of 43.07.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genomic Valley Biotech Ltd:
- Net Profit Margin: 42.19%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.32% (Industry Average ROCE: 16.97%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.13% (Industry Average ROE: 15.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.1
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 92.8 (Industry average Stock P/E: 27.83)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 42.19%